GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: The Anglo Celtic Group OPTION trial

Annals of Oncology

Volumn 28, Issue 8, 2017, Pages 1811-1816

  Leonard, Robert C F ^a   Adamson, D J A ^b   Bertelli, G ^c   Mansi, J ^d   Yellowlees, A ^e   Dunlop, J ^f   Thomas, G A ^a   Coleman, R E ^g   Anderson, R A ^h  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

^c SINGLETON HOSPITAL   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e Qantics Biostatistics   (United Kingdom)

^f INFORMATION SERVICES DIVISION   (United Kingdom)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Breast cancer; Chemoprotection; GnRH analogue; Ovary

Indexed keywords

ANTHRACYCLINE DERIVATIVE; FOLLITROPIN; GOSERELIN; MUELLERIAN INHIBITING FACTOR; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN;

ADULT; AGE; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARIAN RESERVE; PREMATURE OVARIAN FAILURE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; AGONISTS; BREAST TUMOR; CHEMICALLY INDUCED; EARLY DIAGNOSIS;

ADULT; AMENORRHEA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; EARLY DIAGNOSIS; FEMALE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; PRIMARY OVARIAN INSUFFICIENCY; PROSPECTIVE STUDIES;

EID: 85029325182     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx184     Document Type: Article

References (27)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717
2. ESHRE Guideline Group on POI, Webber L, Davies M et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod 2016; 31: 926-937
3. Del Mastro L, Boni L, Michelotti A et al. Effect of the gonadotropinreleasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. Jama 2011; 306: 269-276
4. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009; 91: 694-697
5. Gerber B, von Minckwitz G, Stehle H et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011; 29: 2334-2341
6. Munster PN, Moore AP, Ismail-Khan R et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012; 30: 533-538
7. Elgindy EA, El-Haieg DO, Khorshid OM et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013; 121: 78-86
8. Moore HC, Unger JM, Phillips KA et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015; 372: 923-932
9. Elgindy E, Sibai H, Abdelghani A, Mostafa M. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet Gynecol 2015; 126: 187-195
10. Lambertini M, Ceppi M, Poggio F et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a metaanalysis of randomized studies. Ann Oncol 2015; 26: 2408-2419
11. Demeestere I, Brice P, Peccatori FA et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol 2016; 34: 2568-2574
12. Zhang Y, Xiao Z, Wang Y et al. Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients. PLoS One 2013; 8: e80444
13. Dewailly D, Andersen CY, Balen A et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014; 20: 370-385
14. Partridge AH, Ruddy KJ, Gelber S et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 2010; 94: 638-644
15. Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011; 96: 1336-1343
16. Harlow SD, Gass M, Hall JE et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97: 1159-1168
17. Oktay K, Turan V. Failure of ovarian suppression with gonadotropinreleasing hormone analogs to preserve fertility: an assessment based on the quality of evidence. JAMA Oncol 2016; 2: 74-75
18. Coates AS, Winer EP, Goldhirsch A et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26: 1533-1546
19. Morgan S, Anderson RA, Gourley C et al. How do chemotherapeutic agents damage the ovary?. Hum Reprod Update 2012; 18: 525-535
20. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52: 365-372
21. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod 2004; 19: 1294-1299
22. Anderson RA, Themmen APN, Al Qahtani A et al. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006; 21: 2583-2592
23. Partridge A, Gelber S, Gelber RD et al. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 2007; 43: 1646-1653
24. Anderson RA, Rosendahl M, Kelsey TW, Cameron DA. Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 2013; 49: 3404-3411
25. Su HC, Haunschild C, Chung K et al. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients. Cancer 2014; 120: 3691-3698
26. Wilson C, Gossiel F, Leonard R et al. Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover. J Bone Oncol 2016; 5: 43-49
27. Swain SM, Jeong JH, Geyer CE, Jr et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362: 2053-2065